[New antithrombotic drugs].
Many trials are ongoing in the field of thromboembolic event prevention in atrial fibrillation. These drugs are acting as antithrombin and antifactor Xa. The goal is to obtain drugs that could be as efficient as vitamine K antagonists but that could be more easily used, mainly by avoiding INR measurements.
Le Heuzey
J-Y
JY
Service de Cardiologie A et Rythmologie, Hôpital Européen Georges Pompidou, 20, rue Leblanc, 75015 Paris, France. jean-yves.le-heuzey@egp.aphp.fr
D001281:Atrial Fibrillation / Q000150:complications; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control*
D005343:Fibrinolytic Agents